Search results
- (-) Remove Press releases filter Press releases
Oxford BioMedica Notes Encouraging Results of the Investigator Led Phase I/II clinical trial of MVA-5T4 Immunotherapy (TroVax®) and Low Dose Cyclophosphamide in Patients with Advanced Colorectal Cancer
~ Both Cyclophosphamide and TroVax® independently shown to induce highly beneficial anti-tumour immune responses, resulting in signi
Appointment of New Chief Financial Officer
Oxford, UK – 28 February 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therap
Oxford BioMedica plc Preliminary Results for the year ended 31 December 2016
Oxford, UK – 16 March 2017: Oxford BioMedica plc (LSE: OXB), (“OXB” or “the Group”) a leading gene and cell therapy group, today a
Oxford BioMedica Announces Publication in the Journal Nature Communications on Study Results Supporting the Transgene Repression in vector Production (TRiP) system
~ Data demonstrates benefits of the Group’s proprietary “TRiP” system in enhancing production yields for a broad range of gene therapy vectors
Oxford BioMedica notes acceptance by FDA of a Biologics License Application (BLA) filing for CTL019
Oxford, UK – 30 March 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy gr
Oxford BioMedica to Webcast Presentation at the Jefferies 2017 Healthcare Conference New York
Oxford, UK – 06 June 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy gro
Oxford BioMedica notes FDA Advisory Committee to review CTL019
London, UK - 7 June 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy grou
Oxford BioMedica Notes Findings on CTL019 from Phase II JULIET Study Presented at the 14th Meeting of International Conference on Malignant Lymphoma (ICML)
Oxford, UK – 14 June 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a
Oxford BioMedica Announces Refinancing of Debt Facility
London, UK – 30 June 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy gr